Why the study?
Do atrial natriuretic peptides reduce cancer cell growth in vitro and in athymic mice?
Population
Human pancreatic adenocarcinoma cells, breast adenocarcinomas, squamous cell lung cancer, and small cell…
Design
Preclinical
Follow-up
24 hours (in vitro), 1 week (in vivo)
Authors
Loading...
Does not support clinical use in pancreatic cancer; leaves open therapeutic potential pending human trials.
Do atrial natriuretic peptides reduce cancer cell growth in vitro and in athymic mice?
Atrial natriuretic peptides demonstrate significant anticancer properties, inhibiting DNA synthesis and reducing tumor volume in preclinical models of various adenocarcinomas.
David L. Vesely (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: